ReviewJournal of clinical and translational hepatology2022
Persistently Rising Alpha-fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Review.
Review in Journal of clinical and translational hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Guideline
- The miR-4512/PDZK1IP1 axis in hepatocellular carcinoma: clinical significance, diagnostic value, and functional validation.BMC medical genomics · 2026Article
- Vitamin D receptor gene polymorphism and its association with the susceptibility to Helicobacter pylori infection in the Egyptian population with hepatocellular carcinoma.BMC gastroenterology · 2026Article
- Prognostic Significance of Combined α-Fetoprotein and PIVKA-II for Hepatocellular Carcinoma After Hepatectomy.Journal of hepatocellular carcinoma · 2026Article
- Electrochemical biosensing of alpha-fetoprotein based on carboxylated multi-walled nanotube-polyAzur A (in DES)-gold nanoparticles.Turkish journal of chemistry · 2026Article
- Peri-transplant use of immune checkpoint inhibitors in hepatocellular carcinoma: a transplant oncology perspective on safety, timing, post-transplant management, and future directions.Frontiers in oncology · 2026Review
- Survival of patients with advanced hepatocellular carcinoma based on Gustave Roussy immune score and portal vein tumor thrombosis: a single-center, retrospective, non-randomized case-controlled study.Discover oncology · 2025Article
- Utility of Alpha-Fetoprotein and Protein Induced by Vitamin K Absence or Antagonist-II Kinetics in Predicting Radiologic Response and Survival in Unresectable Hepatocellular Carcinoma Undergoing Immunotherapy.World journal of oncology · 2025Article
- Exposure to low levels of hexavalent chromium in drinking water alters diet-induced steatotic liver disease in male rats.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2025Article
- Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Carcinoma.JCO precision oncology · 2025Article
- Preliminary Evaluation of Plasma circ_0009910, circ_0027478, and miR-1236-3p as Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma.International journal of molecular sciences · 2025Article
- Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection.Langenbeck's archives of surgery · 2025Article
- Alpha-fetoprotein as a prognostic factor in alpha-fetoprotein-negative hepatocellular carcinoma - integration into post-resection prognostic nomograms.Contemporary oncology (Poznan, Poland) · 2025Article
- Tetrahedral DNA-linked aptamer-antibody-based sandwich-type electrochemical sensor with Ag@Au core-shell nanoparticles as a signal amplifier for highly sensitive detection of α-fetoprotein.Mikrochimica acta · 2024Article
- Alpha-fetoprotein: Past, present, and future.Hepatology communications · 2024Review
- Immuno-Kachiks formula immunomodulates and ameliorates hepatic damage induced by monosodium glutamate in rats.Heliyon · 2024Article
- [Multi-omics combined test performance effectiveness on opportunistic screening of high-risk liver cancer population].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Article
- Vitamin D receptor rs3782905 and vitamin D binding protein rs7041 polymorphisms are associated with hepatocellular carcinoma susceptibility in cirrhotic HCV patients.BMC medical genomics · 2023Article
- Prognostic Significance of Alpha-Fetoprotein in Staging of Chronic Hepatitis B Infection.Rwanda journal of medicine and health sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), one of the most common malignant tumors worldwide, is known for its grim prognosis, with untreated life expectancy being only a matter of months after the diagnosis. The difficulty in making a diagnosis early is one of the main contributing factors to the poor prognosis. Alpha-fetoprotein (AFP) had long been used as a surveillance tool, but suboptimal specificity and sensitivity has prompted liver societies to abandon the recommendation for its universal use, even in combination with ultrasonography. Most studies have shown no obvious correlation between serum AFP level and HCC tumor size, stage, or survival post-diagnosis. However, some studies concluded that a gradual rise or persistent elevation in AFP were positive predictors for tumor development. Other studies reported a fall in AFP followed by a rise in patients with HCC as well as persistently rising AFP levels without development of HCC on follow up. Our calculation of the sensitivity and specificity of persistently rising AFP for HCC were both low, at 60% and 35.8%, respectively, indicating that the presence of persistently rising AFP per se did not offer diagnostic benefit. In addition, our calculated mean slopes of persistently rising AFP levels in HCC and non-HCC patients were numerically very different, but the difference was not statistically significant. We conclude that the published data do not support a role for rising AFP levels per se in the diagnosis of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.